Literature DB >> 19858193

Regulated cleavage of prothrombin by prothrombinase: repositioning a cleavage site reveals the unique kinetic behavior of the action of prothrombinase on its compound substrate.

Harlan N Bradford1, Joseph A Micucci, Sriram Krishnaswamy.   

Abstract

Prothrombinase converts prothrombin to thrombin via cleavage at Arg(320) followed by cleavage at Arg(271). Exosite-dependent binding of prothrombin to prothrombinase facilitates active site docking by Arg(320) and initial cleavage at this site. Precise positioning of the Arg(320) site for cleavage is implied by essentially normal cleavage at Arg(320) in recombinant prothrombin variants bearing additional Arg side chains either one or two residues away. However, mutation of Arg(320) to Gln reveals that prothrombinase can cleave prothrombin following Arg side chains shifted by as many as two residues N-terminal to the 320 position at near normal rates. Further repositioning leads to a loss in cleavage at this region with an abrupt shift toward slow cleavage at Arg(271). In contrast, the binding constant for the active site docking step is strongly dependent on the sequence preceding the scissile bond as well as position. Large effects on binding only yield minor changes in rate until the binding constant passes a threshold value. This behavior is expected for a substrate that can engage the enzyme through mutually exclusive active site docking reactions followed by cleavage to yield different products. Cleavage site specificity as well as the ordered action of prothrombinase on its compound substrate is regulated by the thermodynamics of active site engagement of the individual sites as well as competition between alternate cleavage sites for active site docking.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19858193      PMCID: PMC2804180          DOI: 10.1074/jbc.M109.070334

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  43 in total

Review 1.  Exosite-driven substrate specificity and function in coagulation.

Authors:  S Krishnaswamy
Journal:  J Thromb Haemost       Date:  2005-01       Impact factor: 5.824

2.  Ratcheting of the substrate from the zymogen to proteinase conformations directs the sequential cleavage of prothrombin by prothrombinase.

Authors:  Elsa P Bianchini; Steven J Orcutt; Peter Panizzi; Paul E Bock; Sriram Krishnaswamy
Journal:  Proc Natl Acad Sci U S A       Date:  2005-07-08       Impact factor: 11.205

3.  New insights into the regulation of the blood clotting cascade derived from the X-ray crystal structure of bovine meizothrombin des F1 in complex with PPACK.

Authors:  P D Martin; M G Malkowski; J Box; C T Esmon; B F Edwards
Journal:  Structure       Date:  1997-12-15       Impact factor: 5.006

Review 4.  Molecular mechanisms for the conversion of zymogens to active proteolytic enzymes.

Authors:  A R Khan; M N James
Journal:  Protein Sci       Date:  1998-04       Impact factor: 6.725

5.  Purification and characterization of a variant of human prothrombin: prothrombin Segovia.

Authors:  M T Collados; J Fernández; J A Páramo; R Montes; J R Borbolla; L F Montaño; E Rocha
Journal:  Thromb Res       Date:  1997-03-15       Impact factor: 3.944

6.  Gly319 --> arg substitution in the dysfunctional prothrombin Segovia.

Authors:  S Akhavan; E Rocha; S Zeinali; P M Mannucci
Journal:  Br J Haematol       Date:  1999-06       Impact factor: 6.998

7.  Enhanced gamma-carboxylation of recombinant factor X using a chimeric construct containing the prothrombin propeptide.

Authors:  R M Camire; P J Larson; D W Stafford; K A High
Journal:  Biochemistry       Date:  2000-11-21       Impact factor: 3.162

8.  Binding of substrate in two conformations to human prothrombinase drives consecutive cleavage at two sites in prothrombin.

Authors:  Steven J Orcutt; Sriram Krishnaswamy
Journal:  J Biol Chem       Date:  2004-10-19       Impact factor: 5.157

9.  Role of the activation peptide domain in human factor X activation by the extrinsic Xase complex.

Authors:  R J Baugh; S Krishnaswamy
Journal:  J Biol Chem       Date:  1996-07-05       Impact factor: 5.157

10.  The isomorphous structures of prethrombin2, hirugen-, and PPACK-thrombin: changes accompanying activation and exosite binding to thrombin.

Authors:  J Vijayalakshmi; K P Padmanabhan; K G Mann; A Tulinsky
Journal:  Protein Sci       Date:  1994-12       Impact factor: 6.725

View more
  7 in total

Review 1.  The transition of prothrombin to thrombin.

Authors:  S Krishnaswamy
Journal:  J Thromb Haemost       Date:  2013-06       Impact factor: 5.824

2.  Meizothrombin is an unexpectedly zymogen-like variant of thrombin.

Authors:  Harlan N Bradford; Sriram Krishnaswamy
Journal:  J Biol Chem       Date:  2012-07-19       Impact factor: 5.157

3.  Inhibition of thrombin formation by active site mutated (S360A) activated protein C.

Authors:  Gerry A F Nicolaes; Paul E Bock; Kenneth Segers; Karin C A A Wildhagen; Björn Dahlbäck; Jan Rosing
Journal:  J Biol Chem       Date:  2010-05-18       Impact factor: 5.157

4.  A bipartite autoinhibitory region within the B-domain suppresses function in factor V.

Authors:  Mettine H A Bos; Rodney M Camire
Journal:  J Biol Chem       Date:  2012-06-15       Impact factor: 5.157

5.  Contribution of amino acid region 659-663 of Factor Va heavy chain to the activity of factor Xa within prothrombinase .

Authors:  Jamila Hirbawi; John L Vaughn; Michael A Bukys; Hans L Vos; Michael Kalafatis
Journal:  Biochemistry       Date:  2010-09-13       Impact factor: 3.162

6.  Membrane binding by prothrombin mediates its constrained presentation to prothrombinase for cleavage.

Authors:  Harlan N Bradford; Steven J Orcutt; Sriram Krishnaswamy
Journal:  J Biol Chem       Date:  2013-08-12       Impact factor: 5.157

7.  Novel factor VIII variants with a modified furin cleavage site improve the efficacy of gene therapy for hemophilia A.

Authors:  G N Nguyen; L A George; J I Siner; R J Davidson; C B Zander; X L Zheng; V R Arruda; R M Camire; D E Sabatino
Journal:  J Thromb Haemost       Date:  2016-11-25       Impact factor: 5.824

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.